

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CStone Pharmaceuticals
基石藥業

(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2616)

**POLL RESULTS OF ANNUAL GENERAL MEETING
HELD ON JUNE 23, 2020**

Reference is made to the notice of annual general meeting (the “**AGM Notice**”) of CStone Pharmaceuticals (the “**Company**”) dated May 22, 2020. The board of directors of the Company (the “**Board**”) is pleased to announce that all the resolutions (the “**Resolutions**”) set out in the AGM Notice were duly passed by the shareholders of the Company as ordinary resolutions by way of poll at the annual general meeting of the Company held on June 23, 2020 (the “**AGM**”).

The poll results in respect of the Resolutions are as follows:

Ordinary Resolutions		No. of Votes Cast (%)		Total No. of Votes Cast (%)
		For	Against	
1.	To receive and consider the audited consolidated financial statements of the Company and the reports of the directors and auditors for the year ended December 31, 2019.	729,054,118 (100.00%)	0 (0.00%)	729,054,118 (100.00%)
2.	(i) To re-elect Mr. Guobin Zhang as a non-executive director of the Company;	706,147,482 (96.82%)	23,163,636 (3.18%)	729,311,118 (100.00%)
	(ii) To re-elect Dr. Lian Yong Chen as a non-executive director of the Company; and	705,985,982 (96.80%)	23,325,136 (3.20%)	729,311,118 (100.00%)
	(iii) To re-elect Mr. Ting Yuk Anthony Wu as an independent non-executive director of the Company.	714,841,795 (98.02%)	14,469,323 (1.98%)	729,311,118 (100.00%)

Ordinary Resolutions		No. of Votes Cast (%)		Total No. of Votes Cast (%)
		For	Against	
3.	To authorise the board of directors to fix the remuneration of the directors of the Company.	707,659,668 (97.04%)	21,613,950 (2.96%)	729,273,618 (100.00%)
4.	To re-appoint Deloitte Touche Tohmatsu as auditors and authorise the board of directors of the Company to fix their remuneration.	728,779,818 (99.93%)	531,300 (0.07%)	729,311,118 (100.00%)
5.	To grant options to Dr. Frank Ningjun Jiang (“ Dr. Jiang ”) under the Post-IPO ESOP to subscribe for an aggregate of 40,480,421 shares of the Company.	674,060,750 (94.52%)	39,069,300 (5.48%)	713,130,050 (100.00%)
6.	To give a specific mandate to the directors to allot and issue 9,108,095 shares of the Company to Dr. Jiang.	684,598,999 (96.00%)	28,531,051 (4.00%)	713,130,050 (100.00%)
7.	To give a general mandate to the directors to allot, issue and deal with additional shares not exceeding 20% of the issued share capital of the Company.	665,331,317 (91.23%)	63,942,301 (8.77%)	729,273,618 (100.00%)
8.	To give a general mandate to the directors to repurchase shares not exceeding 10% of the issued share capital of the Company.	729,273,618 (100.00%)	0 (0.00%)	729,273,618 (100.00%)
9.	To extend the authority given to the directors pursuant to ordinary resolution no. 7 to issue shares by adding to the issued share capital of the Company the number of shares repurchased under ordinary resolution no. 8.	663,849,794 (91.02%)	65,461,324 (8.98%)	729,311,118 (100.00%)

Notes:

1. As more than 50% of the votes were cast in favour of each of the Resolutions, all the Resolutions proposed at the AGM were duly passed as ordinary resolutions.
2. The full text of the Resolutions is set out in the AGM Notice.

3. Dr. Jiang and his associates, directly and indirectly, holding an aggregate of 22,941,068 shares of the Company, representing approximately 2.23% of the total issued share capital of the Company as at the date of the AGM, abstained from voting on the Resolutions No. 5 and No. 6 proposed at the AGM. The total shares entitling Shareholders to attend and vote on Resolutions No. 5 and No. 6 proposed at the AGM were 1,005,579,041 shares, and the total shares entitling Shareholders to attend and vote on resolutions other than Resolutions No. 5 and No. 6 proposed at the AGM were 1,028,520,109 shares. To the best of the knowledge, information and belief of the Board, and having made all reasonable enquiries:
- (i) there were no Shareholders who were entitled to attend the AGM but was required to abstain from voting in favor of the Resolutions proposed at the AGM as set out in Rule 13.40 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”);
 - (ii) none of the Shareholders was required under the Listing Rules to abstain from voting on any of the Resolutions proposed at the AGM, except that Dr. Jiang and his associates are required to abstain from voting on Resolutions No. 5 and No. 6; and
 - (iii) save as disclosed above, there was no restriction on any Shareholders to cast votes on any of the Resolutions proposed at the AGM and none of the Shareholders have stated their intention in the circular of the Company dated May 22, 2020 to vote against or to abstain from voting on any of the Resolutions at the AGM.
4. Computershare Hong Kong Investor Services Limited, the Company’s Hong Kong share registrar, was appointed as the scrutineer at the AGM for the purpose of vote-taking in respect of the Resolutions.

By Order of the Board
CStone Pharmaceuticals
Dr. Frank Ningjun Jiang
Chairman

Shanghai, June 23, 2020

As at the date of this announcement, the Board of Directors of the Company comprises Dr. Frank Ningjun Jiang as Chairman and Executive Director, Dr. Wei Li, Mr. Qun Zhao, Mr. Yanling Cao, Mr. Guobin Zhang and Dr. Lian Yong Chen as non-executive Directors, and Dr. Paul Herbert Chew, Mr. Ting Yuk Anthony Wu and Mr. Hongbin Sun as independent non-executive Directors.